Shorter 4-Month Regimen (High-dose Rifapentine, Isoniazid, Pyrazinamide, Moxifloxacin then High-dose Rifapentine, Isoniazid, Moxifloxacin for active TB)

Treatment for Drug-susceptible tuberculosis

Typical Dosage: Rifapentine 1200mg daily, Isoniazid 300mg daily, Pyrazinamide 1000-1500mg daily, Moxifloxacin 400mg daily

Effectiveness
94%
Safety Score
55%
Clinical Trials
15
Participants
8K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
Rifapentine 1200mg daily, Isoniazid 300mg daily, Pyrazinamide 1000-1500mg daily, Moxifloxacin 400mg daily
Time to Effect
2-4 weeks for clinical improvement, 2 months for sputum conversion
Treatment Duration
4 months
Evidence Quality
HIGH
Number Needed to Harm (NNH)
20(Treat 20 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,300
Monitoring:$1,000
Side Effect Mgmt:$450
Total Annual:$3,750
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$12,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$3,989
Cost per Remission
$4,167
Comparison vs Standard 6-Month Regimen (2HRZE/4HR)
Cost Difference
+$1,550/year
More expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
No dominance
Shorter 4-Month Regimen (High-dose Rifapentine, Isoniazid, Pyrazinamide, Moxifloxacin then High-dose Rifapentine, Isoniazid, Moxifloxacin for active TB) Outcomes

for Drug-susceptible tuberculosis

Efficacy Outcomes
Overall Effectiveness
+94%
Response Rate
+94%
Remission Rate
+90%
Common Side Effects
Hepatotoxicity (Grade 1-4)
+15%
GI upset (nausea, vomiting, diarrhea)
+25%
Peripheral neuropathy
+15%
Rash
+10%
Arthralgia
+20%
QT prolongation
+3%
Tendinopathy
+1%

Sources:

cdc.gov
nih.gov
medicaldialogues.in
Clinical Trials
Studies investigating Shorter 4-Month Regimen (High-dose Rifapentine, Isoniazid, Pyrazinamide, Moxifloxacin then High-dose Rifapentine, Isoniazid, Moxifloxacin for active TB) for Drug-susceptible tuberculosis
Failed to load clinical trials